Soft urology and continence lead to Q1 21 miss
07/05/21 -"Coloplast reported mixed Q2/H1 2021 numbers. Sales were up 2% on an organic basis, driven by ostomy (+4%) and urology (+3%). Adjusted EBIT was up 2% with the associated margin at 33% (+100bp). FY21 ..."
Pages
60
Language
English
Published on
07/05/21
You may also be interested by these reports :
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
09/04/24
bioMerieux has reported better-than-expected Q1 organic sales growth, with healthy growth visible across both segments. Besides this, a promising ...